What Happened?
Shares of biopharmaceutical company Bristol Myers Squibb (NYSE: BMY) jumped 2.6% in the afternoon session after its positive momentum continued as the company received expanded approvals for its key cancer drug, Opdivo. The new approvals broadened the potential market for Opdivo, allowing its use in more treatment situations. This development improved the drug's competitive standing against other treatments for blood cancers and supported the long-term growth potential of the company's cancer drug business.
The shares closed the day at $58.95, up 2.6% from previous close.
Is now the time to buy Bristol-Myers Squibb? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Bristol-Myers Squibb’s shares are not very volatile and have only had 6 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 6 months ago when the stock gained 5.5% on the news that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to its experimental antibody, BMS-986446, for the treatment of early Alzheimer's disease.
This special status was intended to help speed up the development and review of drugs that treat serious conditions where there is an unmet medical need. The drug candidate, which was in a mid-stage trial, aimed to slow or delay the progression of Alzheimer's. Adding to the positive news, Bristol Myers Squibb also announced it had joined a consortium with other pharmaceutical companies, including Takeda and Astex, to use artificial intelligence to improve the drug discovery process.
Bristol-Myers Squibb is up 10.3% since the beginning of the year, and at $58.97 per share, it is trading close to its 52-week high of $62.37 from February 2026. Despite the year-to-date gain, investors who bought $1,000 worth of Bristol-Myers Squibb’s shares 5 years ago would now be looking at only $939.08.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
